bupivacaine and am-356
bupivacaine has been researched along with am-356 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bedoya, M; Decher, N; González, W; Kiper, AK; Ramírez, D; Rinné, S | 1 |
| Furness, JB; Hunne, B; Matsuyama, H; McHugh, D; Needham, K; Nguyen, TV; Thacker, M | 1 |
Reviews
1 review(s) available for bupivacaine and am-356
| Article | Year |
|---|---|
TASK Channels Pharmacology: New Challenges in Drug Design.
Topics: Animals; Drug Design; Drug Discovery; Humans; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Tandem Pore Domain | 2019 |
Other Studies
1 other study(ies) available for bupivacaine and am-356
| Article | Year |
|---|---|
Evidence that TASK1 channels contribute to the background current in AH/type II neurons of the guinea-pig intestine.
Topics: Action Potentials; Anesthetics, Local; Animals; Arachidonic Acids; Bupivacaine; Dose-Response Relationship, Drug; Electric Stimulation; Female; Gene Expression Regulation; Guinea Pigs; Hydrogen-Ion Concentration; In Vitro Techniques; Intestines; Lectins; Male; Membrane Potentials; Nerve Tissue Proteins; Neurons; Patch-Clamp Techniques; Phosphopyruvate Hydratase; Potassium Channels, Tandem Pore Domain; Potassium Chloride; RNA, Messenger; Time Factors | 2008 |